Poziotinib is a quinazoline derivative substituted with (3,4-dichloro-2-fluorophenyl)amino at position 4, [1-(prop-2-enoyl)piperidin-4-yl]oxy at position 6, and methoxy at position 7. It is a potent, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 with exon 20 insertion mutations. It functions as an antineoplastic agent, apoptosis inducer, and epidermal growth factor receptor antagonist. It belongs to the classes of quinazolines, N-acylpiperidines, aromatic ethers, diethers, secondary amines, dichlorobenzenes, monofluorobenzenes, substituted anilines, and acrylamides.
